Connection

CHAD CREIGHTON to Receptors, Estrogen

This is a "connection" page, showing publications CHAD CREIGHTON has written about Receptors, Estrogen.
Connection Strength

1.028
  1. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 2010; 12(3):R40.
    View in: PubMed
    Score: 0.251
  2. Coactivation of Estrogen Receptor and IKK? Induces a Dormant Metastatic Phenotype in ER-Positive Breast Cancer. Cancer Res. 2018 02 15; 78(4):974-984.
    View in: PubMed
    Score: 0.105
  3. Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Mol Cancer Res. 2016 05; 14(5):470-81.
    View in: PubMed
    Score: 0.093
  4. Comprehensive molecular portraits of human breast tumours. Nature. 2012 Oct 04; 490(7418):61-70.
    View in: PubMed
    Score: 0.073
  5. Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. Breast Cancer Res Treat. 2012 Jul; 134(2):583-93.
    View in: PubMed
    Score: 0.072
  6. SGK3 is associated with estrogen receptor expression in breast cancer. Breast Cancer Res Treat. 2012 Jul; 134(2):531-41.
    View in: PubMed
    Score: 0.071
  7. A gene transcription signature of obesity in breast cancer. Breast Cancer Res Treat. 2012 Apr; 132(3):993-1000.
    View in: PubMed
    Score: 0.067
  8. SAFB1 mediates repression of immune regulators and apoptotic genes in breast cancer cells. J Biol Chem. 2010 Feb 05; 285(6):3608-3616.
    View in: PubMed
    Score: 0.060
  9. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008 Feb 01; 68(3):826-33.
    View in: PubMed
    Score: 0.053
  10. A gene transcription signature associated with hormone independence in a subset of both breast and prostate cancers. BMC Genomics. 2007 Jun 28; 8:199.
    View in: PubMed
    Score: 0.051
  11. Reprogramming of the estrogen responsive transcriptome contributes to tamoxifen-dependent protection against tumorigenesis in the p53 null mammary epithelial cells. PLoS One. 2018; 13(3):e0194913.
    View in: PubMed
    Score: 0.027
  12. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol. 2017 Apr 01; 35(10):1061-1069.
    View in: PubMed
    Score: 0.025
  13. Uterine ALK3 is essential during the window of implantation. Proc Natl Acad Sci U S A. 2016 Jan 19; 113(3):E387-95.
    View in: PubMed
    Score: 0.023
  14. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 2014 Sep 11; 16(5):430.
    View in: PubMed
    Score: 0.021
  15. Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience. Ann Surg Oncol. 2013 Jul; 20(7):2364-72.
    View in: PubMed
    Score: 0.019
  16. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res. 2011 Apr 15; 17(8):2314-27.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.